Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort

dbNSFP v3.0: A One-Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice-Site SNVs

(2016) Xiaoming Liu et al.   HUMAN MUTATION

Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis

(2016) D Juskevicius et al.   LEUKEMIA

The significance of FOXP1 in diffuse large B-cell lymphoma

(2016) Duncan M. Gascoyne et al.   LEUKEMIA & LYMPHOMA

Expression of CD40 is a positive prognostic factor of diffuse large B-cell lymphoma treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)

(2016) Guoqi Song et al.   OncoTargets and Therapy

Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

(2015) Felicitas Hitz et al.   ANNALS OF HEMATOLOGY

Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas

(2015) R. D. Morin et al.   CLINICAL CANCER RESEARCH

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)

(2015) Christoph Mamot et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study

(2015) Alexandar Tzankov et al.   Journal of Hematology & Oncology

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

(2015) Alessandro Pastore et al.   LANCET ONCOLOGY

The Genetic Landscape of Diffuse Large B-Cell Lymphoma

(2015) Laura Pasqualucci et al.   SEMINARS IN HEMATOLOGY

Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies

(2015) C. Dong et al.   HUMAN MOLECULAR GENETICS

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

(2014) D. W. Scott et al.   BLOOD

False Positives in Multiplex PCR-Based Next-Generation Sequencing Have Unique Signatures

(2014) Chad M. McCall et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

(2014) C Fernández-Rodríguez et al.   LEUKEMIA

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Analysis of FOXO1 mutations in diffuse large B-cell lymphoma

(2013) D. L. Trinh et al.   BLOOD

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing

(2013) R. D. Morin et al.   BLOOD

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

(2013) Alexandar Tzankov et al.   MODERN PATHOLOGY

Genetic heterogeneity of diffuse large B-cell lymphoma

(2013) Jenny Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

(2012) Z. Y. Xu-Monette et al.   BLOOD

CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia

(2012) A Inthal et al.   LEUKEMIA

CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab

(2011) K. Miyazaki et al.   ANNALS OF ONCOLOGY

The molecular pathogenesis of primary mediastinal large B-cell lymphoma

(2011) C. Steidl et al.   BLOOD

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

(2011) G. Salles et al.   BLOOD

CREBBP mutations in relapsed acute lymphoblastic leukaemia

(2011) Charles G. Mullighan et al.   NATURE

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE

Analysis of the coding genome of diffuse large B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE GENETICS

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

(2011) J. W. Friedberg   Hematology-American Society of Hematology Education Program

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494

(2010) J. N. Winter et al.   CLINICAL CANCER RESEARCH

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE